

# Sanjay J Mathew

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3695880/publications.pdf>

Version: 2024-02-01

167  
papers

11,677  
citations

36303

51  
h-index

30087

103  
g-index

172  
all docs

172  
docs citations

172  
times ranked

9550  
citing authors

#	ARTICLE	IF	CITATIONS
1	Does mismatch negativity have utility for NMDA receptor drug development in depression?. Revista Brasileira De Psiquiatria, 2022, 44, 61-73.	1.7	3
2	Deep Brain Stimulation for Depression Informed by Intracranial Recordings. Biological Psychiatry, 2022, 92, 246-251.	1.3	58
3	Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology, 2022, 47, 1088-1095.	5.4	12
4	A Novel Approach to Link Genetics and Human MRI Identifies AKAP7-Dependent Subicular/Prefrontal Functional Connectivity as Altered in Suicidality. Chronic Stress, 2022, 6, 247054702210837.	3.4	1
5	A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. Expert Opinion on Drug Safety, 2022, 21, 745-759.	2.4	1
6	Nighttime Sleep Quality and Daytime Sleepiness Predicts Suicide Risk in Adults Admitted to an Inpatient Psychiatric Hospital. Behavioral Sleep Medicine, 2022, , 1-13.	2.1	1
7	An Update on Community Ketamine Practices. American Journal of Psychiatry, 2022, 179, 393-394.	7.2	13
8	Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 2021, 24, 383-391.	2.1	28
9	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. Translational Psychiatry, 2021, 11, 88.	4.8	27
10	Wearable technology: A promising opportunity to improve inpatient psychiatry safety and outcomes. Journal of Psychiatric Research, 2021, 135, 104-106.	3.1	3
11	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. American Journal of Psychiatry, 2021, 178, 437-446.	7.2	33
12	Distinct trajectories of antidepressant response to intravenous ketamine. Journal of Affective Disorders, 2021, 286, 320-329.	4.1	8
13	Vortioxetine Versus Placebo for Major Depressive Disorder. Journal of Clinical Psychiatry, 2021, 82, .	2.2	16
14	Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHVA5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depression and Anxiety, 2021, 38, 1108-1119.	4.1	6
15	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. European Neuropsychopharmacology, 2021, 49, 122-132.	0.7	17
16	A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-d-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology, 2021, 46, 820-827.	5.4	15
17	Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. , 2021, 33, e10-e20.		8
18	A Case of Intranasal Ketamine Misuse: Considerations for Clinical Practice. Journal of Psychiatric Practice, 2021, 27, 492-495.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	7.9	235
20	Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. <i>Psychophysiology</i> , 2020, 57, e13356.	2.4	19
21	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020, 260, 131-139.	4.1	21
22	Q-15 checks and 1:1 observations: Exacerbating a problem we are trying to solve?. <i>Journal of Affective Disorders</i> , 2020, 263, 552-554.	4.1	6
23	Psychotherapy for Mixed Depression and Mixed Mania. <i>Psychiatric Clinics of North America</i> , 2020, 43, 199-211.	1.3	3
24	Cortical Gamma as a Marker of Kynurenine Pathway Engagement in Healthy Veterans Receiving L-4-Chloro-Kynurenine (AV-101). <i>Biological Psychiatry</i> , 2020, 87, S265.	1.3	0
25	Impulsivity and Suicidal Behavior. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 47, 179-195.	1.7	13
26	Ketamine for depression clinical issues. <i>Advances in Pharmacology</i> , 2020, 89, 131-162.	2.0	20
27	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 287-292.	1.4	25
28	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , 2020, 45, 1656-1663.	5.4	50
29	A randomized proof-of-mechanism trial applying the "fast-fail" approach to evaluating $\mu$ -opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , 2020, 26, 760-768.	30.7	129
30	Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change. <i>American Journal of Psychiatry</i> , 2020, 177, 107-109.	7.2	3
31	Objective measurement of sleep, heart rate, heart rate variability, and physical activity in suicidality: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 273, 318-327.	4.1	15
32	The Evidence for Ketamine in Mood Disorders. <i>Psychiatric Annals</i> , 2020, 50, 44-45.	0.1	0
33	Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression?. <i>American Journal of Psychiatry</i> , 2020, 177, 891-894.	7.2	2
34	Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. <i>Molecular Psychiatry</i> , 2019, 24, 576-587.	7.9	130
35	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 539-547.	0.5	4
36	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. <i>Journal of Psychiatric Research</i> , 2019, 110, 166-171.	3.1	41

#	ARTICLE	IF	CITATIONS
37	Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opinion on Investigational Drugs, 2019, 28, 1003-1012.	4.1	15
38	116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective $\mu$ -Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. Biological Psychiatry, 2019, 85, S48-S49.	1.3	0
39	The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression. Pharmaceuticals, 2019, 12, 133.	3.8	17
40	Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression. Contemporary Clinical Trials Communications, 2019, 16, 100432.	1.1	8
41	Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. Journal of Affective Disorders, 2019, 258, 102-108.	4.1	16
42	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology, 2019, 44, 1233-1238.	5.4	35
43	A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. American Journal of Psychiatry, 2019, 176, 923-930.	7.2	94
44	Does the Opioid System Block or Enhance the Antidepressant Effects of Ketamine?. Chronic Stress, 2019, 3, 247054701985207.	3.4	6
45	Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. Journal of Affective Disorders, 2019, 251, 248-255.	4.1	25
46	5 Clinical Evaluation of the Abuse Potential of Buprenorphine/Samidorphan Combination. CNS Spectrums, 2019, 24, 176-176.	1.2	0
47	Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180132.	4.0	9
48	A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD. Frontiers in Psychiatry, 2019, 10, 846.	2.6	13
49	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression and Anxiety, 2019, 36, 235-243.	4.1	37
50	Electroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemporary Clinical Trials, 2019, 77, 19-26.	1.8	34
51	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nature Reviews Drug Discovery, 2019, 18, 82-84.	46.4	52
52	Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. Journal of Affective Disorders, 2018, 229, 1-13.	4.1	7
53	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder. Journal of Clinical Psychopharmacology, 2018, 38, 200-206.	1.4	13
54	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal of Psychiatry, 2018, 175, 150-158.	7.2	476

#	ARTICLE	IF	CITATIONS
55	DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , 2018, 10, 136.	4.1	36
56	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , 2018, 8, 280.	4.8	26
57	F172. Clinical Evaluation of Abuse Potential of ALKS 5461. <i>Biological Psychiatry</i> , 2018, 83, S305.	1.3	1
58	Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass, and Behavioral Correlates. <i>Chronic Stress</i> , 2018, 2, 247054701876845.	3.4	6
59	F179. Epigenetic Biomarkers in Women With Posttraumatic Stress Disorder After CRF1 Receptor Antagonist Treatment. <i>Biological Psychiatry</i> , 2018, 83, S308.	1.3	0
60	Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. <i>Journal of Affective Disorders</i> , 2018, 241, 514-518.	4.1	33
61	The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2017, 42, 1739-1746.	5.4	94
62	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 399.	11.0	433
63	Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 566-574.	1.5	72
64	549. DNA Methylation Biomarkers and Treatment Effects of a Corticotropin Releasing Hormone Type 1 Receptor Antagonist in a Biologically-Defined Subset of PTSD-Patients. <i>Biological Psychiatry</i> , 2017, 81, S222.	1.3	1
65	A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2017, 42, 2567-2574.	5.4	36
66	Targeting glutamate signalling in depression: progress and prospects. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 472-486.	46.4	345
67	Neurometabolic Abnormalities in Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2017, 174, 3-5.	7.2	7
68	The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress. <i>Chronic Stress</i> , 2017, 1, 247054701770399.	3.4	62
69	525. The Temporal Stability of Cognitive Functioning and Functional Capacity in Women with PTSD. <i>Biological Psychiatry</i> , 2017, 81, S213.	1.3	0
70	130. Childhood Trauma and Impulsivity in Adult Mood and Anxiety Disorders: Evidence of Behavioral Sensitization?. <i>Biological Psychiatry</i> , 2017, 81, S54-S55.	1.3	0
71	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. <i>Biological Psychiatry</i> , 2017, 82, 866-874.	1.3	74
72	Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 697-707.	3.2	2

#	ARTICLE	IF	CITATIONS
73	Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. <i>Neuropsychopharmacology</i> , 2017, 42, 844-853.	5.4	99
74	Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders. <i>Neuropsychopharmacology</i> , 2017, 42, 1179-1181.	5.4	30
75	Operationalizing NIMH Research Domain Criteria (RDoC) in naturalistic clinical settings. <i>Bulletin of the Menninger Clinic</i> , 2016, 80, 187-212.	0.6	12
76	Patterns of anterior versus posterior white matter fractional anisotropy concordance in adult nonhuman primates: Effects of early life stress. <i>Journal of Affective Disorders</i> , 2016, 192, 167-175.	4.1	7
77	Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder. <i>Journal of Affective Disorders</i> , 2016, 190, 414-423.	4.1	15
78	Computational Approaches for Studying Mechanisms of Psychiatric Disorders. , 2016, , .		2
79	Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 454-459.	1.4	9
80	Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. <i>Neuropsychopharmacology</i> , 2015, 40, 1084-1090.	5.4	117
81	Hippocampal volume and the rapid antidepressant effect of ketamine. <i>Journal of Psychopharmacology</i> , 2015, 29, 591-595.	4.0	67
82	Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, e170-e171.	1.8	5
83	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , 2015, 1345, 47-58.	3.8	70
84	Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2015, 25, 1082-1090.	0.7	52
85	A Novel Anxiety and Affective Spectrum Disorder of Mind and Body—The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 93-103.	1.8	7
86	Does Ketamine Have Anti-Suicidal Properties? Current Status and Future Directions. <i>CNS Drugs</i> , 2015, 29, 181-188.	5.9	39
87	Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. <i>Current Psychiatry Reports</i> , 2015, 17, 81.	4.5	21
88	Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. <i>Translational Psychiatry</i> , 2015, 5, e509-e509.	4.8	93
89	Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 247-252.	2.2	179
90	Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 342.	2.0	38

#	ARTICLE	IF	CITATIONS
91	Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disorders. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 440.	2.0	18
92	EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION. <i>Depression and Anxiety</i> , 2014, 31, 335-343.	4.1	275
93	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. <i>Psychopharmacology</i> , 2014, 231, 481-488.	3.1	73
94	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , 2014, 57, 51-57.	3.1	35
95	Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 240.	1.6	41
96	In vivo 1H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. <i>Neuroscience Letters</i> , 2014, 569, 74-79.	2.1	45
97	Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight. <i>NeuroImage: Clinical</i> , 2014, 4, 326-335.	2.7	21
98	Therapeutic infusions of ketamine: Do the psychoactive effects matter?. <i>Drug and Alcohol Dependence</i> , 2014, 136, 153-157.	3.2	98
99	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 331-336.	2.1	195
100	The Emerging Use of Ketamine for Anesthesia and Sedation in Traumatic Brain Injuries. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 390-395.	3.9	80
101	Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression. <i>Biological Psychiatry</i> , 2013, 74, 250-256.	1.3	632
102	Glycine Transporter-1 Inhibitors: A New Class of Antidepressant?. <i>Biological Psychiatry</i> , 2013, 74, 710-711.	1.3	9
103	A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. <i>European Neuropsychopharmacology</i> , 2013, 23, 276-284.	0.7	58
104	Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2013, 170, 1134-1142.	7.2	965
105	S.7.3 - KETAMINE AND NMDA RECEPTOR MODULATION FOR TREATMENT-RESISTANT MOOD DISORDERS. <i>Behavioural Pharmacology</i> , 2013, 24, e8-e9.	1.7	0
106	Riluzole effect on occipital cortex: A structural and spectroscopy pilot study. <i>Neuroscience Letters</i> , 2012, 530, 103-107.	2.1	16
107	Ketamine for Treatment-Resistant Unipolar Depression. <i>CNS Drugs</i> , 2012, 26, 189-204.	5.9	203
108	Ketamine for Depression: Where Do We Go from Here?. <i>Biological Psychiatry</i> , 2012, 72, 537-547.	1.3	353

#	ARTICLE	IF	CITATIONS
109	Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. <i>Bipolar Disorders</i> , 2012, 14, 64-70.	1.9	57
110	Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. <i>NMR in Biomedicine</i> , 2012, 25, 1073-1087.	2.8	134
111	Tryptophan Depletion and Emotional Processing in Healthy Volunteers at High Risk for Depression. <i>Biological Psychiatry</i> , 2011, 69, 804-807.	1.3	36
112	Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeys. <i>Physiology and Behavior</i> , 2011, 103, 535-539.	2.1	4
113	A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. <i>European Neuropsychopharmacology</i> , 2011, 21, 221-229.	0.7	44
114	Ketamine Treatment for Major Depression. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2011, 46, 89-96.	0.1	1
115	Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 37-44.	1.8	78
116	The Relationship between Intelligence and Anxiety: An Association with Subcortical White Matter Metabolism. <i>Frontiers in Evolutionary Neuroscience</i> , 2011, 3, 8.	3.7	21
117	The Implications of Neurocognitive Deficits in Posttraumatic Stress Disorder. <i>Psychiatric Annals</i> , 2011, 41, 408-412.	0.1	4
118	A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 414-415.	2.2	37
119	Early-life stress and neurometabolites of the hippocampus. <i>Brain Research</i> , 2010, 1358, 191-199.	2.2	19
120	Increased ventricular lactate in chronic fatigue syndrome measured by <sup>1</sup> H MRS imaging at 3.0 T. II: comparison with major depressive disorder. <i>NMR in Biomedicine</i> , 2010, 23, 643-650.	2.8	68
121	A pilot study of the effects of chronic paroxetine administration on hippocampal N-acetylaspartate in generalized anxiety disorder. <i>Journal of Psychopharmacology</i> , 2010, 24, 1175-1181.	4.0	18
122	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 71-82.	2.1	239
123	Diffusion tensor imaging in studying white matter complexity: A gap junction hypothesis. <i>Neuroscience Letters</i> , 2010, 475, 161-164.	2.1	7
124	The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates. <i>Neuroscience Letters</i> , 2010, 480, 93-96.	2.1	65
125	Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2010, 67, 139-145.	1.3	589
126	Overcoming Antidepressant Treatment Resistance: Focus on Glutamate. <i>Modern Problems of Pharmacopsychiatry</i> , 2010, , 89-100.	2.5	1



#	ARTICLE	IF	CITATIONS
127	Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs, 2010, 24, 669-693.	5.9	156
128	Publication Bias and the Efficacy of Antidepressants. American Journal of Psychiatry, 2009, 166, 140-145.	7.2	50
129	Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an <i>in vivo</i> 3.0 T <sup>1</sup> H MRS imaging study. NMR in Biomedicine, 2009, 22, 251-258.	2.8	68
130	Neurobiological mechanisms in major depressive disorder. Cmaj, 2009, 180, 305-313.	2.0	348
131	Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder. Biological Psychiatry, 2009, 65, 792-800.	1.3	227
132	Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression. Biological Psychiatry, 2009, 66, 522-526.	1.3	525
133	Drs. Mathew and Charney Reply. American Journal of Psychiatry, 2009, 166, 934-934.	7.2	1
134	Treatment-resistant depression: recent developments and future directions. Depression and Anxiety, 2008, 25, 989-992.	4.1	42
135	Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2008, 148C, 89-98.	1.6	139
136	Anxiety disorders: a comprehensive review of pharmacotherapies. Mount Sinai Journal of Medicine, 2008, 75, 248-262.	1.9	130
137	Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. Mount Sinai Journal of Medicine, 2008, 75, 263-275.	1.9	13
138	Anxiety and depression: leading edge of therapy. Mount Sinai Journal of Medicine, 2008, 75, 171-173.	1.9	3
139	Novel Drugs and Therapeutic Targets for Severe Mood Disorders. Neuropsychopharmacology, 2008, 33, 2080-2092.	5.4	199
140	Hippocampal N-Acetylaspartate Concentration and Response to Riluzole in Generalized Anxiety Disorder. Biological Psychiatry, 2008, 63, 891-898.	1.3	61
141	Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics, 2008, 30, 1658-1666.	2.5	6
142	Effects of PRX-00023, a Novel, Selective Serotonin 1A Receptor Agonist on Measures of Anxiety and Depression in Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 235-239.	1.4	21
143	Pharmacotherapy for Generalized Anxiety Disorder. , 2008, , .		2
144	Glutamate and anxiety disorders. Current Psychiatry Reports, 2007, 9, 278-283.	4.5	41

#	ARTICLE	IF	CITATIONS
145	Maternal-Infant Response to Variable Foraging Demand in Nonhuman Primates: Effects of Timing of Stressor on Cerebrospinal Fluid Corticotropin-Releasing Factor and Circulating Glucocorticoid Concentrations. <i>Annals of the New York Academy of Sciences</i> , 2006, 1071, 525-533.	3.8	37
146	Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: Relationship to IQ and early trauma. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 27-39.	1.8	41
147	Etiology and neurobiology of social anxiety disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 12, 9-13.	2.2	19
148	Neurobiology of anxiety disorders and implications for treatment. <i>Mount Sinai Journal of Medicine</i> , 2006, 73, 941-9.	1.9	93
149	Synchronized Maternal-Infant Elevations of Primate CSF CRF Concentrations in Response to Variable Foraging Demand. <i>CNS Spectrums</i> , 2005, 10, 530-536.	1.2	48
150	Glutamate Modulation in Mood and Anxiety Disorders: Toward a Rational Pharmacology?. <i>CNS Spectrums</i> , 2005, 10, 806-807.	1.2	5
151	Glutamate modulators as novel interventions for mood disorders. <i>Revista Brasileira De Psiquiatria</i> , 2005, 27, 243-248.	1.7	42
152	Open-Label Trial of Riluzole in Generalized Anxiety Disorder. <i>American Journal of Psychiatry</i> , 2005, 162, 2379-2381.	7.2	119
153	Dorsolateral Prefrontal Cortical Pathology in Generalized Anxiety Disorder: A Proton Magnetic Resonance Spectroscopic Imaging Study. <i>American Journal of Psychiatry</i> , 2004, 161, 1119-1121.	7.2	74
154	Twenty-four-hour cortisol secretion patterns in prepubertal children with anxiety or depressive disorders. <i>Biological Psychiatry</i> , 2004, 56, 198-204.	1.3	83
155	A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. <i>Biological Psychiatry</i> , 2003, 54, 727-735.	1.3	93
156	Differentiating Depressed Adolescent 24h Cortisol Secretion in Light of Their Adult Clinical Outcome. <i>Neuropsychopharmacology</i> , 2003, 28, 1336-1343.	5.4	54
157	Cerebrospinal Fluid Concentrations of Biogenic Amines and Corticotropin-releasing Factor in Adolescent Non-human Primates as a Function of the Timing of Adverse Early Rearing. <i>Stress</i> , 2002, 5, 185-193.	1.8	43
158	Molecular targets in the treatment of anxiety. <i>Biological Psychiatry</i> , 2002, 52, 1008-1030.	1.3	147
159	Neurobiology of early life stress: Nonhuman primate models. <i>Seminars in Clinical Neuropsychiatry</i> , 2002, 7, 96-103.	1.9	48
160	Effects of LY354740, a Novel Glutamatergic Metabotropic Agonist, on Nonhuman Primate Hypothalamic-Pituitary-Adrenal Axis and Noradrenergic Function. <i>CNS Spectrums</i> , 2001, 6, 607-617.	1.2	17
161	Glutamate-Hypothalamic-Pituitary-Adrenal Axis Interactions: Implications for Mood and Anxiety Disorders. <i>CNS Spectrums</i> , 2001, 6, 555-564.	1.2	39
162	Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder. <i>Depression and Anxiety</i> , 2001, 14, 199-208.	4.1	13

#	ARTICLE	IF	CITATIONS
163	Neurobiological Mechanisms of Social Anxiety Disorder. American Journal of Psychiatry, 2001, 158, 1558-1567.	7.2	148
164	Treatment Strategies for Obsessive-Compulsive Disorder. Psychiatric Annals, 2000, 30, 699-708.	0.1	3
165	Attitudes Toward Neurosurgical Procedures for Parkinson's Disease and Obsessive-Compulsive Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 259-267.	1.8	16
166	Molecular imaging of other anxiety disorders. , 0, , 295-307.		0
167	Ketamine in treatment-resistant depression. , 0, , 345-357.		1